340 related articles for article (PubMed ID: 30358114)
1. Management of arterial hypertension with angiotensin receptor blockers: Current evidence and the role of olmesartan.
Omboni S; Volpe M
Cardiovasc Ther; 2018 Dec; 36(6):e12471. PubMed ID: 30358114
[TBL] [Abstract][Full Text] [Related]
2. Triple Combination Therapies Based on Olmesartan: A Personalized Therapeutic Approach to Improve Blood Pressure Control.
Volpe M; Santolamazza C; Mastromarino V; Coluccia R; Battistoni A; Tocci G
High Blood Press Cardiovasc Prev; 2017 Sep; 24(3):255-263. PubMed ID: 28608025
[TBL] [Abstract][Full Text] [Related]
3. Monotherapy and Dual Combination Therapies Based on Olmesartan: A Comprehensive Strategy to Improve Blood Pressure Control.
Volpe M; Santolamazza C; Mastromarino V; Coluccia R; Battistoni A; Tocci G
High Blood Press Cardiovasc Prev; 2017 Sep; 24(3):243-253. PubMed ID: 28608026
[TBL] [Abstract][Full Text] [Related]
4. Olmesartan/amlodipine: a review of its use in the management of hypertension.
Kreutz R
Vasc Health Risk Manag; 2011; 7():183-92. PubMed ID: 21490944
[TBL] [Abstract][Full Text] [Related]
5. Angiotensin Receptor Blockers Versus Angiotensin Converting Enzyme Inhibitors for the Treatment of Arterial Hypertension and the Role of Olmesartan.
Omboni S; Volpe M
Adv Ther; 2019 Feb; 36(2):278-297. PubMed ID: 30591990
[TBL] [Abstract][Full Text] [Related]
6. Olmesartan medoxomil-based antihypertensive therapy evaluated by ambulatory blood pressure monitoring: efficacy in high-risk patient subgroups.
Chrysant SG; Germino FW; Neutel JM
Am J Cardiovasc Drugs; 2012 Dec; 12(6):375-89. PubMed ID: 23116225
[TBL] [Abstract][Full Text] [Related]
7. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K
Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
[TBL] [Abstract][Full Text] [Related]
8. Combination therapy for hypertension: focus on high-dose olmesartan medoxomil (40 mg) plus hydrochlorothiazide.
Rump LC; Sellin L
Expert Opin Pharmacother; 2010 Sep; 11(13):2231-42. PubMed ID: 20707758
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of olmesartan medoxomil in patients with mild to moderate essential hypertension: the OLMEBEST Study.
Barrios V; Boccanelli A; Ewald S; Girerd X; Heagerty A; Krzesinski JM; Lins R; Rodicio J; Stefenelli T; Woittiez A; Böhm M
Clin Drug Investig; 2007; 27(8):545-58. PubMed ID: 17638395
[TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy and safety of olmesartan/hydrochlorothiazide combination therapy in patients with essential hypertension.
Ruilope LM
Vasc Health Risk Manag; 2008; 4(6):1237-48. PubMed ID: 19337537
[TBL] [Abstract][Full Text] [Related]
11. Olmesartan vs. ramipril in elderly hypertensive patients: review of data from two published randomized, double-blind studies.
Omboni S; Malacco E; Mallion JM; Fabrizzi P; Volpe M
High Blood Press Cardiovasc Prev; 2014 Mar; 21(1):1-19. PubMed ID: 24435506
[TBL] [Abstract][Full Text] [Related]
12. Antihypertensive effects of olmesartan compared with other angiotensin receptor blockers: a meta-analysis.
Wang L; Zhao JW; Liu B; Shi D; Zou Z; Shi XY
Am J Cardiovasc Drugs; 2012 Oct; 12(5):335-44. PubMed ID: 22920046
[TBL] [Abstract][Full Text] [Related]
13. Triple combination therapy to improve blood pressure control: experience with olmesartan-amlodipine-hydrochlorothiazide therapy.
Tocci G; Paneni F; Passerini J; Volpe M
Expert Opin Pharmacother; 2012 Dec; 13(18):2687-97. PubMed ID: 23170911
[TBL] [Abstract][Full Text] [Related]
14. Effect of antihypertensive treatment on 24-h blood pressure variability: pooled individual data analysis of ambulatory blood pressure monitoring studies based on olmesartan mono or combination treatment.
Omboni S; Kario K; Bakris G; Parati G
J Hypertens; 2018 Apr; 36(4):720-733. PubMed ID: 29045341
[TBL] [Abstract][Full Text] [Related]
15. Long-term efficacy of olmesartan medoxomil in Chinese hypertensive patients as assessed by clinic, ambulatory and home blood pressure measurements.
Wang JG; Sun NL; Ke YN; Zhang BH; Ikegami N; Zhu JR
Clin Drug Investig; 2012 Nov; 32(11):729-34. PubMed ID: 23018282
[TBL] [Abstract][Full Text] [Related]
16. Olmesartan medoxomil for the treatment of hypertension in children and adolescents.
Tocci G; Volpe M
Vasc Health Risk Manag; 2011; 7():177-81. PubMed ID: 21490943
[TBL] [Abstract][Full Text] [Related]
17. Improving Adherence to Treatment and Reducing Economic Costs of Hypertension: The Role of Olmesartan-Based Treatment.
Costa FV
High Blood Press Cardiovasc Prev; 2017 Sep; 24(3):265-274. PubMed ID: 28695464
[TBL] [Abstract][Full Text] [Related]
18. Beating the clock: reducing cardiovascular risk by rapid blood pressure reduction with olmesartan.
Barrios V; Escobar C
Expert Opin Pharmacother; 2010 Jun; 11(9):1549-58. PubMed ID: 20446761
[TBL] [Abstract][Full Text] [Related]
19. Optimal therapeutic strategy for treating patients with hypertension and atherosclerosis: focus on olmesartan medoxomil.
Mason RP
Vasc Health Risk Manag; 2011; 7():405-16. PubMed ID: 21796255
[TBL] [Abstract][Full Text] [Related]
20. Antihypertensive efficacy of olmesartan medoxomil alone and in combination with hydrochlorothiazide.
Chrysant SG; Chrysant GS
Expert Opin Pharmacother; 2004 Mar; 5(3):657-67. PubMed ID: 15013933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
